

Date: 17th October, 2022

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai - 400 001

Dear Sir / Madam,

Subject: USFDA inspection at Alembic Pharmaceuticals' Oncology Injectable Formulation Facility at Panelav

We would like to inform that the United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' Oncology Injectable Formulation Facility located at Panelav from 4th October, 2022 to 14th October, 2022. The USFDA issued a Form 483 with 4 procedural observations.

None of the observations are related to data integrity and management believes that they are addressable.

The Company is preparing the response to the observations, which will be submitted to the USFDA within stipulated period.

The Company is committed to maintain the highest quality standards and compliance at all times.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED